Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efruxifermin in Compensated Cirrhosis Due to NASH/MASH
NCT06528314Phase 3Recruiting
- Sponsor
- Akero Therapeutics
- Start
- Oct 2024
- Primary completion
- Feb 2030
- Countries
- 21
01
Overview
A Phase 3 trial of efruxifermin in Nonalcoholic steatohepatitis (NASH), sponsored by Akero Therapeutics. Started Oct 2024; status: recruiting.
02
Drugs
efruxifermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06528314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528314.